Novo Nordisk's Pipeline Momentum Meets a Harder Earnings Test
Published on 11/15/2026 at 03:11 | Editorial boerse-global.de
Novo Nordisk shares closed Friday up 2.7%, with media reports pointing to the EU approval of FREHEMGO as the trigger. Yet the more consequential question for investors sits beneath the day's move: can the company convert a widening set of product wins into durable earnings power?
The haemophilia green light allows FREHEMGO to be used for routine prophylaxis in adults and children with haemophilia A, covering patients both with and without inhibitors. Novo plans its first European launches next year, and patients will be able to choose between monthly, fortnightly or weekly dosing. That flexibility is part of the approved treatment profile; the commercial payoff only arrives if the rollout succeeds.
CagriSema's headline number comes with a condition
Fresh Phase 3 data add a second front. In the REDEFINE 9 trial, Novo reported an estimated average weight loss of 20.7% and 21.0% for the two lower-dose combinations after 68 weeks, against 2.0% in the placebo arm. The findings were presented at ObesityWeek and published in The Lancet Diabetes & Endocrinology.
The caveat lies in the method. Those figures assume every patient stayed on treatment throughout the period studied. Anyone extrapolating future revenue from the results has to carry that assumption into their valuation. A bullish case can lean on the reported efficacy, provided it states the condition explicitly; a cautious approach will want confirmation from further development before gaining stronger conviction.
That is the gap between a promising trial readout and a bankable business expectation. The magnitude of the weight loss speaks for Novo; what decides its economic weight is execution.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The earnings picture is more nuanced than the headline
Novo set its financial marker on 4 November, when it raised full-year guidance. Adjusted and reported operating profit then diverged. In the third quarter of 2026, adjusted operating profit rose 27% in constant currencies to DKK 31,720 million — support for the bull case if the improvement carries into the coming quarters. Reported operating profit, by contrast, fell 9% in constant currencies, a figure that included non-cash impairments of DKK 8.7 billion.
Guidance for 2026 now points to a constant-currency change of between -2% and +2% for both adjusted sales and adjusted operating profit. The raised range still stretches from a decline to modest growth, so direction within that band is what matters. A result near the top would back the view that Novo is regaining operational traction; one near the bottom would show how limited the room remains despite the upgrade.
Berenberg lifted its earnings estimates on Friday but kept its rating at "Hold", according to media reports. The call came ahead of an expected CagriSema market launch in early 2027, tying better profit expectations to restraint on the investment verdict.
Wegovy data add breadth, regulation adds friction
Elsewhere in the portfolio, Novo reported on 8 November a post-hoc analysis of the Phase III ESSENCE study. In adults with MASH, liver scarring and a BMI below 27 kg/m², treatment was linked to improvements in several disease markers, including liver injury, fibrosis and disease activity. The findings round out Wegovy's medical profile, though a post-hoc look carries correspondingly limited weight.
Regulatory risk cuts the other way. On Monday the US Food and Drug Administration asked makers of GLP-1 receptor agonists to add new warnings, affecting Novo's Ozempic and Wegovy. The subject is the potentially elevated risk of the rare eye condition NAION. The FDA cited 6.4 cases per 100,000 person-years among GLP-1 users versus 3.8 in the comparison group. An earlier report, dated 9 November, put the analysis at roughly six cases per 100,000 patients who had taken a GLP-1 drug for at least a year.
That safety requirement matters because it touches the risk assessment of the drugs concerned. The bear case would gain weight if safety concerns dent their use — a risk to expectations rather than a reported business development.
What to watch into 2027
A concrete regulatory catalyst is expected in 2027, when Novo anticipates FDA and EMA decisions on Etavopivat for sickle cell disease. The applications reported yesterday rest on the Phase III HIBISCUS programme.
Until then, execution takes centre stage: solid profits and the planned European rollout of FREHEMGO. Should Novo underpin its raised guidance operationally and push the launches forward, a more lasting recovery stays plausible. If adjusted earnings momentum fades, the foundation of that view weakens — and the assumption behind the CagriSema numbers will weigh more heavily in the valuation.
Ad
Novo Nordisk Stock: New Analysis - 15 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
